Evaluation of synthetic, M type-specific peptides as antigens in a multivalent group A streptococcal vaccine

Area of Science:

• Microbiology
• Immunology
• Vaccine Development

Background:

• Group A streptococci (GAS) cause various diseases, necessitating effective prevention strategies.
• emm gene sequencing enables M serotype prevalence determination, crucial for vaccine design.
• A multivalent vaccine targeting prevalent M serotypes could prevent most GAS-mediated diseases in the USA.

Purpose of the Study:

• To evaluate the immunogenicity and protective efficacy of synthetic, M type-specific peptides derived from prevalent GAS serotypes in a mouse model.
• To assess the potential of these peptides as components of a multivalent GAS vaccine.

Main Methods:

• Synthesized nine M type-specific peptides from the N-termini of three prevalent GAS serotypes.
• Assessed immunogenicity and functional activity (bactericidal assay) of peptide-induced sera in mice.
• Conducted in vivo nasopharyngeal challenge experiments to evaluate protection against GAS colonization.

Main Results:

• At least one immunogenic peptide was identified for each of the three M types tested.
• Five of nine synthetic peptides elicited an immune response; sera from four peptides showed functional activity.
• Peptides M1-3 and M3-2 significantly reduced intranasal GAS carriage (90% and 66% reduction, respectively).
• M3-2 peptide immunization provided cross-protection against a heterologous M43 serotype challenge (67% colonization reduction).

Conclusions:

• Synthetic, M type-specific peptides are effective antigens for a multivalent GAS vaccine.
• These findings support the development of a peptide-based vaccine to prevent GAS-mediated diseases.